Ian Read
Field force changes. We have -- I may ask Olivier to expand on this, but we structured our field force in a way that we can make changes for the LOE in the coming, and the new products that are coming in, so I don't expect any material disruption to our field force over this period. And in fact, I think we have good morale in our field force right now. Olivier, do you want to add anything to that?
Olivier Brandicourt
So Pfizer field force organization in the U.S. is now appropriately sized to support the broader Primary Care portfolio over the coming years. We have 10 assets being promoted next year and afterwards, hopefully, including Eliquis. So the attention of our representative assigned to detail Lipitor today would shift to other assets at the appropriate time.
So why the secrecy? Just tell us!!!